Simcere Pharmaceutical Group Ltd. (S2P)

Overview

Simcere Pharmaceutical Group Limited is a prominent enterprise in China's pharmaceutical industry, focusing on the research, development, manufacture, and sales of pharmaceutical products. Catering to distributors and pharmacy chains, as well as other pharmaceutical manufacturers within China, the company has established a significant presence in the market. Its operations are centered around a broad spectrum of therapeutic areas that include oncology, central nervous system disorders, autoimmune diseases, anti-infection measures, and cardiovascular health, among others. Established in 1995 and based in Nanjing, China, Simcere not only emphasizes product innovation but also partners strategically with other entities, such as Vivoryon Therapeutics N.V., to widen its impact in the Greater China region. Beyond its pharmaceutical pursuits, Simcere also participates in manufacturing pharmaceutical ingredients and engages in a property management business, showcasing the company's diversified interests within and beyond the healthcare sector.

Products and Services

• Sanbexin: A concentrated solution for injection, combining edaravone and dexborneol, designed primarily for acute ischemic stroke treatment, highlighting the company's commitment to addressing critical central nervous system challenges.
• Endostar: This recombinant human endostatin injection stands out as an anti-angiogenic agent used in cancer therapy, part of Simcere's focused efforts in the oncology therapeutic area.
• ENWEIDA: An envafolimab injection, showcasing Simcere's advancement in immunotherapy options for cancer patients, reflecting ongoing innovations in oncology.
• COSELA: Trilaciclib hydrochloride for injection, a novel approach designed to protect bone marrow from the impact of chemotherapy, further illustrating Simcere’s investment in supportive cancer care.
• Iremod: An iguratimod tablet that represents Simcere's venture into treatments for autoimmune diseases, specifically rheumatoid arthritis, showcasing its commitment to a broad therapeutic portfolio.
• XIANNUOXIN: Comprises simnotrelvir tablets/ritonavir tablets, a combination pointing towards Simcere's efforts in addressing viral infections, thereby diversifying its anti-infection product line.

In addition to its diverse product range, Simcere Pharmaceutical Group Limited provides promotional services for pharmaceutical products, ensuring a comprehensive approach to healthcare solutions. This aspect of their service underscores the company's integrated strategy in pharmaceutical manufacture and market penetration.